Literature DB >> 19104776

Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake.

Martin Weber1, Sonja Talmon, Ilka Schulze, Christine Boeddinghaus, Gerhard Gross, Hans Schoemaker, Karsten M Wicke.   

Abstract

RATIONALE: Most antidepressants (AD) directly or indirectly enhance the serotonergic tone in the CNS. Since the serotonin system is involved in both, the modulation of mood and motor behavior, it was reasoned that these drugs might also interfere with running wheel activity (RWA), a form of positively motivated motor behavior, which might be linked to pathological states like obsessive-compulsive disorder (OCD).
OBJECTIVES: We used RWA to characterize ADs from all major classes. Effects on RWA were compared to effects on general locomotor activity (LOC) to control for unspecific effects on general locomotion.
METHODS: Two hours before lights-off, mice were treated with either vehicle or one of the following AD: the selective serotonin reuptake inhibitors (SSRIs) citalopram (3-10 mg/kg), paroxetine (1-10 mg/kg) and fluoxetine (2-6.6 mg/kg), the selective norepinephrine reuptake inhibitor (SNRI) reboxetine (1-10 mg/kg), the monoamine oxidase (MAO) inhibitors tranylcypromine (1-3 mg/kg) and moclobemide (3-10 mg/kg), and the tricyclic ADs desipramine and imipramine (10-30 mg/kg, each). LOC and RWA were measured after lights-off.
RESULTS: At the highest dose tested, all ADs, with the exception of the MAO inhibitors, significantly reduced RWA. Both tricyclics inhibited RWA only at doses that similarly affected LOC. In contrast, all SSRI and reboxetine inhibited RWA at doses that left LOC unaffected.
CONCLUSIONS: SSRI and the SNRI reboxetine inhibit RWA at doses not suppressing LOC. RWA may represent a simple behavioral readout of positively motivated behavior that merits further attention for psychopharmacology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104776     DOI: 10.1007/s00213-008-1420-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  39 in total

Review 1.  The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.

Authors:  C A Naranjo; D M Knoke
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 2.  The therapeutic potential of monoamine oxidase inhibitors.

Authors:  Moussa B H Youdim; Dale Edmondson; Keith F Tipton
Journal:  Nat Rev Neurosci       Date:  2006-04       Impact factor: 34.870

3.  Reboxetine: attenuation of intravenous nicotine self-administration in rats.

Authors:  Anthony S Rauhut; Stephanie N Mullins; Linda P Dwoskin; Michael T Bardo
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

4.  The reinforcing property and the rewarding aftereffect of wheel running in rats: a combination of two paradigms.

Authors:  Terry W Belke; Jason P Wagner
Journal:  Behav Processes       Date:  2005-02-28       Impact factor: 1.777

Review 5.  New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence.

Authors:  Falk Kiefer; Karl Mann
Journal:  Eur J Pharmacol       Date:  2005-11-02       Impact factor: 4.432

6.  A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence.

Authors:  Conor K Farren; Stephanie O'Malley
Journal:  Am J Addict       Date:  2002

7.  Techniques for establishing schedules with wheel running as reinforcement in rats.

Authors:  I H Iversen
Journal:  J Exp Anal Behav       Date:  1993-07       Impact factor: 2.468

8.  Intracranial reward after Lilly 110140 (fluoxetine HCl): evidence for an inhibitory role for serotonin.

Authors:  R J Katz; B J Carroll
Journal:  Psychopharmacology (Berl)       Date:  1977-01-31       Impact factor: 4.530

9.  Attenuation of food-restriction-induced running by chronic fluoxetine treatment.

Authors:  M Altemus; J R Glowa; D L Murphy
Journal:  Psychopharmacol Bull       Date:  1993

10.  Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice.

Authors:  Paola Casti; Giorgio Marchese; Gianluca Casu; Stefania Ruiu; Luca Pani
Journal:  Neuropharmacology       Date:  2004-07       Impact factor: 5.250

View more
  17 in total

1.  Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats.

Authors:  Pai-Kai Huang; Shawn M Aarde; Deepshikha Angrish; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-06-03       Impact factor: 4.492

2.  d-Amphetamine and methylmercury exposure during adolescence alters sensitivity to monoamine uptake inhibitors in adult mice.

Authors:  Steven R Boomhower; M Christopher Newland
Journal:  Neurotoxicology       Date:  2019-02-12       Impact factor: 4.294

Review 3.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

4.  Comparison of neurogenic effects of fluoxetine, duloxetine and running in mice.

Authors:  Michael W Marlatt; Paul J Lucassen; Henriette van Praag
Journal:  Brain Res       Date:  2010-04-08       Impact factor: 3.252

5.  Predictive validity of a non-induced mouse model of compulsive-like behavior.

Authors:  D M Greene-Schloesser; E A Van der Zee; D K Sheppard; M R Castillo; K A Gregg; T Burrow; H Foltz; M Slater; A Bult-Ito
Journal:  Behav Brain Res       Date:  2011-02-21       Impact factor: 3.332

6.  Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.

Authors:  Diana M Norden; Raymond Devine; Sabahattin Bicer; Runfeng Jing; Peter J Reiser; Loren E Wold; Jonathan P Godbout; Donna O McCarthy
Journal:  Physiol Behav       Date:  2014-12-30

7.  Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease.

Authors:  Michael W Marlatt; Michelle C Potter; Thomas A Bayer; Henriette van Praag; Paul J Lucassen
Journal:  Curr Top Behav Neurosci       Date:  2013

8.  Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex.

Authors:  Robert P Carson; Cary Fu; Peggy Winzenburger; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2012-10-09       Impact factor: 6.150

9.  The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Authors:  Gor Sarkisyan; Amanda J Roberts; Peter B Hedlund
Journal:  Behav Brain Res       Date:  2010-01-25       Impact factor: 3.332

10.  Influence of sex and corticotropin-releasing factor pathways as determinants in serotonin sensitivity.

Authors:  Jonathan G McEuen; Katharine A Semsar; Maria A Lim; Tracy L Bale
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.